As-Needed Versus Regular Use of Fluticasone Furoate Nasal Spray in Patients with Moderate to Severe, Persistent, Perennial Allergic Rhinitis: A Randomized Controlled Trial

Thongngarm, Torpong; Wongsa, Chamard; Phinyo, Phichayut; Assanasen, Paraya; Tantilipikorn, Pongsakorn; Sompornrattanaphan, Mongkhon

doi:10.1016/j.jaip.2020.09.057

Cited by 11 publications

(35 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no rapid drug resistance, and the treatment was well tolerated [ 38 ]. In another 6-week randomized controlled trial, 108 participants were assigned to fluticasone furoate twice a day for 6 weeks and found improvements in their nasal symptom scores and quality of life in rhinoconjunctivitis [ 39 ]. A comparison review of the efficacy of the second generation of nasal corticosteroids, such as ciclesonide, fluticasone furoate, fluticasone propionate, and mometasone furoate, indicates that there is not enough evidence that different types of corticosteroid sprays have different effects.…”

Section: Drugs For Nasal Administrationmentioning

confidence: 99%

Different Methods and Formulations of Drugs and Vaccines for Nasal Administration

et al. 2022

View full text Add to dashboard Cite

Nasal drug delivery is advantageous when compared with other routes of drug delivery as it avoids the hepatic first-pass effect, blood–brain barrier penetration, and compliance issues with parenteral administration. However, nasal administration also has some limitations, such as its low bioavailability due to metabolism on the mucosal surface, and irreversible damage to the nasal mucosa due to the ingredients added into the formula. Moreover, the method of nasal administration is not applicable to all drugs. The current review presents the nasal anatomy and mucosal environment for the nasal delivery of vaccines and drugs, as well as presents various methods for enhancing nasal absorption, and different drug carriers and delivery devices to improve nasal drug delivery. It also presents future prospects on the nasal drug delivery of vaccines and drugs.

show abstract

Section: Drugs For Nasal Administrationmentioning

confidence: 99%

Different Methods and Formulations of Drugs and Vaccines for Nasal Administration

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Twenty-five records underwent the full-text screening, of which 17 studies were excluded. Finally, eight studies were included in the qualitative and quantitative analysis (7,(19)(20)(21)(22)(23)(24)(25) . Characteristics and outcomes of the included trials are displayed in Table 1.…”

Section: Data Synthesis and Statistical Analysismentioning

confidence: 99%

“…Eight hundred and eighty-two patients were included from eight studies (7,(19)(20)(21)(22)(23)(24)(25) . The mean age of each study ranged from 11.6 to 42.8 years.…”

Section: Participantsmentioning

confidence: 99%

“…Four hundred and five patients (46%) were male. Six studies enrolled adult participants (7,(19)(20)(21)(22)25) , one study recruited only pediatric patients (24) , and the other had a mixed population (23) . Seven trials evaluated patients with seasonal AR (19)(20)(21)(22)(23)(24)(25) and one trial assessed perennial AR (7) .…”

Section: Participantsmentioning

confidence: 99%

“…The link between the upper and lower airways has been observed which leads to a concept of united airway disease (6) . The as-need INCS as a treatment step for AR has gained more attention from researchers and studies on the as-need INCS are increasing (7) . In general, INCS is recommended for long-term daily use because its accumulation effects reach the maximum level after at least two weeks of usage.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

As-needed intranasal corticosteroid spray for allergic rhinitis: a systematic review and meta-analysis

Hoang¹,

Chitsuthipakorn²,

Seresirikachorn³

et al. 2022

Rhin

View full text Add to dashboard Cite

Background: As-needed intranasal corticosteroid spray (INCS) is commonly used by patients with allergic rhinitis (AR) who have suboptimal symptom control. This systematic review aimed to assess the effectiveness of as-needed INCS for treating AR. Methodology: Systematic searches for randomized controlled trials studying the effects of as-needed INCS compared to regular INCS, as-needed antihistamine, or placebo were performed. Primary outcomes were total nasal symptom score (TNSS) and disease-specific quality of life (DSQoL). Results: Eight studies (882 participants) met the criteria. Regular use of INCS showed greater improvements than as-needed INCS in TNSS, DSQoL, nasal peak inspiratory flow, sneezing, and nasal congestion scores with small effect sizes. There were no differences between regular and as-needed INCS usage for ocular symptoms, symptom-free days, nasal itching, and rhinorrhea scores. As-needed INCS was superior to as-needed antihistamine and placebo with medium effect sizes. There were no differences in risk of adverse events between the groups in all three comparisons. Conclusions: Regular use of INCS improved total nasal symptoms score and DSQoL better than as-needed INCS. However, as-needed INCS improved TNSS better than as-needed antihistamine and placebo. The effects of as-needed INCS were closer to regular INCS usage than to placebo or as-needed AH usage.

show abstract

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

As-Needed Versus Regular Use of Fluticasone Furoate Nasal Spray in Patients with Moderate to Severe, Persistent, Perennial Allergic Rhinitis: A Randomized Controlled Trial

Cited by 11 publications

References 30 publications

Different Methods and Formulations of Drugs and Vaccines for Nasal Administration

Different Methods and Formulations of Drugs and Vaccines for Nasal Administration

As-needed intranasal corticosteroid spray for allergic rhinitis: a systematic review and meta-analysis

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Contact Info

Product

Resources

About